Bleeding as a complication of liver disease can occur in the absence ofrecognised haemostatic defects. It 
It has been recognised for many years that abnormal bleeding and coagulation problems are associated with liver disease. In a recent review, Kelly and Tuddenham' highlighted the large number of coagulation abnormalities that may occur in liver disease and showed that these may be inter-related. Nonetheless, bleeding problems may also occur in the absence of obvious coagulation abnormalities. In a study of 200 patients, Ewe2 could find no correlation between 'liver bleeding time' at laparoscopic biopsy and standard coagulation tests.
Heparan sulphate is a highly sulphated endogenous heparinoid which normally constitutes a small proportion of the free fraction of plasma glycosaminoglycans.3 It is found in high concentration in endothelial cells and has some anticoagulant activity. 4 Its function is not fully understood, but its presence in blood vessels suggests a role in the prevention of intravascular thrombosis. In Table I shows the characteristics of the patients with liver disease included in the first study. The median plasma heparan sulphate value was 1000 ng/ml (interquartile (IQ) range 375-3000 ng/ml). In a control population of 30 healthy individuals normal values were less than 600 ng/ml (median 280; range <200-600 ng/ml). Twenty nine of the 49 patients in our study had a plasma heparan sulphate concentration of greater than 600 ng/ml. In 27 patients who had experienced an upper gastrointestinal bleed within the previous 28 days (median 5 days before sampling; IQ range 2-15 days) the median plasma heparan sulphate value was 1700 ng/ml (IQ range 900-3900) compared with 390 ng/ml (IQ range 256-800) in 22 patients who had had no recent bleed (p<0.01) (Fig 1) . High heparan sulphate concentrations were also associated with poor liver function, as assessed by modified Child's grading (median (IQ range); Child's grade A -500 ng/ml (256-1800); grade B -615 ng/ml (252-1700); grade C -2500 ng/ml (620-4200)) but this did not reach statistical significance (p<05).
There was no association between the plasma heparan sulphate concentration and coagulation Previous work on heparin clearance in liver disease is contradictory but this may well be because of the use of activity rather than concentration as a measurement of the heparin level. In studies using heparin activity measurements, Simon'`found increased clearance of heparin in liver disease whereas Sette"' could only demonstrate increased clearance in fulminant hepatic failure but not in chronic liver disease patients. In support of our own findings, Teien'7 has reported a decrease in heparin clearance when heparin concentration measurements are used.
It therefore seems likely that the increase in plasma heparan sulphate concentrations in some liver disease patients are caused by reduced 1 clearance by the diseased liver. The statistically significant observation of increased plasma half life in these relatively stable cirrhotic patients is underlined by the fact that none had experienced recent upper gastrointestinal bleeds and that they had better liver function than most of the patients investigated in the first part of the study.
